Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-12-04

FDA Approved: HARVONI — Supplemental Application (Gilead Sciences, Inc)

View source ↗

Summary

FDA approved a supplemental application for HARVONI (ledipasvir/sofosbuvir) submitted by Gilead Sciences, Inc., resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HARVONI (Ledipasvir and Sofosbuvir)

Snippet

SUPPL AP for HARVONI (LEDIPASVIR AND SOFOSBUVIR)